Guest Editors
Matteo Bassetti
Professor of Infectious Diseases, Department of Health Science, University of Genoa, Genoa, Italy
Head, Infectious Diseases Clinic, Hospital Policlinico San Martino-IRCCS, Genoa, Italy
matteo.bassetti@hsanmartino.it
Teena Chopra
Professor of Medicine, Division of Infectious Diseases,
Corporate Medical Director, Infection Prevention, Epidemiology, and Antibiotic Stewardship,
Detroit Medical Center and Wayne State University
tchopra@med.wayne.edu
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Real-World Evidence for Oritavancin Use in Gram-Positive Infections. Drugs - Real World Outcomes 7 (Suppl 1), 1 (2020). https://doi.org/10.1007/s40801-020-00197-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40801-020-00197-5